Academic freedom in clinical research

被引：56

作者：

Nathan, DG ^{[1
]}

Weatherall, DJ

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Univ Oxford, Oxford OX3 9DS, England

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2002年 / 347卷 / 17期

关键词：

D O I：

10.1056/NEJMsb020394

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：1368 / 1371

页数：4

共 30 条

[1]

[Anonymous], 2001, NATURE, V409, P119

[2] TOXICITY OF ORAL IRON CHELATOR L1 [J].

BERDOUKAS, V ;

BENTLEY, P ;

FROST, H ;

SCHNEBLI, HP .

LANCET, 1993, 341 (8852) :1088-1088

[3] EFFICACY OF DEFEROXAMINE IN PREVENTING COMPLICATIONS OF IRON OVERLOAD IN PATIENTS WITH THALASSEMIA MAJOR [J].

BRITTENHAM, GM ;

GRIFFITH, PM ;

NIENHUIS, AW ;

MCLAREN, CE ;

YOUNG, NS ;

TUCKER, EE ;

ALLEN, CJ ;

FARRELL, DE ;

HARRIS, JW .

NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (09) :567-573

[4]

CHOUDHURY R, 1995, DRUG METAB DISPOS, V23, P314

[5]

CRANTON J, 2001, COMMUNICATION 1219

[6]

Davidoff F, 1999, ANN INTERN MED, V130, P246

[7] Sponsorship, authorship, and accountability. [J].

Davidoff, F ;

DeAngelis, CD ;

Drazen, JM ;

Hoey, J ;

Hojgaard, L ;

Horton, R ;

Kotzin, S ;

Nicholls, MG ;

Nylenna, M ;

Overbeke, AJPM ;

Sox, HC ;

Van Der Weyden, MB ;

Wilkes, MS .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (11) :825-827

[8] Factors influencing effectiveness of deferiprone in a thalassaemia major clinical setting [J].

Del Vecchio, GC ;

Crollo, E ;

Schettini, F ;

Fischer, R ;

De Mattia, D .

ACTA HAEMATOLOGICA, 2000, 104 (2-3) :99-102

[9]

HIDER RC, 1990, ANN NY ACAD SCI, V612, P327

[10] Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients [J].

Hoffbrand, AV ;

Al-Refaie, F ;

Davis, B ;

Siritanakatkul, N ;

Jackson, BFA ;

Cochrane, J ;

Prescott, E ;

Wonke, B .

BLOOD, 1998, 91 (01) :295-300

← 1 2 3 →